The present disclosure is directed to the use of modified NK cells for immunotherapy in combination with an antibody, or antigen-binding fragment thereof, to induce an enhanced antibody-dependent cellular cytotoxicity (ADCC) effect.
Provided are natural killer cells engineered to express a chimeric antigen receptor (CAR) with Toll/interleukin-1 (IL-1) receptor (TIR) signaling domains, such as a Toll-like receptor (TLR) signaling domain or a IL-1 receptor (IL-1R) subfamily signaling domain. Further provided are compositions and methods for making and using such natural killer cells in immunotherapy for cancer. The CAR-NK cells may be CISH−/−iPSC-NK cells.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
3.
METHODS AND COMPOSITIONS FOR GENERATING MODIFIED CELLS
The present disclosure relates, in part, to modified cells (e.g, modified pluripotent cells, modified myeloid progenitor cells, modified monocytes, and modified macrophages) comprising certain genetic modifications, which modulate the phenotypes of the modified cells or that of macrophages derived therefrom. The present disclosure further relates to compositions and cell populations comprising the modified cells and methods of making and using the same.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Strategies, systems, compositions, and methods for genetically modifying cells to include one or more loss-of-function modifications and/or to include one or more gain-of-function modifications, as well as modified cells (and compositions of such cells) that include one or more loss-of-function modifications and/or that include one or more gain-of-function modifications, are described. In certain aspects, such modified cells include at least one gain-of-function modification within a coding region of an essential gene.
The present disclosure relates, in part, to methods and compositions for generating modified pluripotent cells, such as modified pluripotent cells comprising a polynucleotide encoding a chimeric antigen receptor (CAR) and genetic disruption of (a) a signal regulatory protein alpha (SIRPA) gene; (b) a cytokine inducible SH2 containing protein (CISH) gene; and/or (c) a sialic acid-binding Ig-like lectin 10 (SIGLEC10) gene, and derivates thereof (e.g., modified myeloid progenitor cells, modified monocytes, and/or modified macrophages).
Strategies, systems, compositions, and methods for genetically modifying cells to include one or more loss-of-function modifications and/or to include one or more gain-of-function modifications, as well as modified cells (and compositions of such cells) that include one or more loss-of-function modifications and/or that include one or more gain-of-function modifications, are described. In certain aspects, such modified cells include at least one gain-of-function modification within a coding region of an essential gene.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Provided herein at chimeric receptors comprising an IgG Fc receptor and toll/interleukin- 1 receptor (TIR) signaling domain. Further provided are immune effector cells (e.g., NK cells) expressing said chimeric receptors and methods for using the same.
The present disclosure relates, in part, to methods and compositions for generating monocytes, macrophages, and/or precursors thereof (such as an induced pluripotent stem cell), comprising (i) a chimeric antigen receptor (CAR); (ii) a polynucleotide encoding a CAR; (iii) a CAR polypeptide; and/or (iv) a vector comprising a polynucleotide encoding a CAR. Methods for treating a cancer using cells expressing the CAR are also provided herein. In some embodiments, the cells expressing the CAR comprise a genetic disruption of a S1RPA gene, CISH gene, and/or SIGLEC10 gene.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Research and development regarding cell-based immunotherapies and regenerative medicine; immunotherapy and regenerative medicine drug development services; providing information in the fields of regenerative medicine research and immunotherapy research; scientific study and research in the fields of immunotherapy research and regenerative medicine Providing information in the fields of regenerative medicine
